Tirzepatide led to significant weight loss over 12 months in people with obesity or overweight

Tirzepatide was assessed for effectiveness in commercially insured individuals without diabetes eligible for obesity medications.

• The study involved individuals who had not previously used glucagon like-peptide-1 receptor agonists and those who had experience with them.
• Real-world effectiveness of tirzepatide may vary between GLP-1 RA-naïve and GLP-1 RA-experienced individuals.
• Findings could help inform treatment decisions for patients seeking obesity management without diabetes.

Simplified